These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31472914)

  • 1. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milestones in the pathogenesis and management of primary liver cancer.
    Nault JC; Cheng AL; Sangro B; Llovet JM
    J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
    [No Abstract]   [Full Text] [Related]  

  • 5. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
    Parks AL; McWhirter RM; Evason K; Kelley RK
    J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
    Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
    Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
    Stefanini B; Tonnini M; Marseglia M; Tovoli F
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic treatment of liver and biliary tumors].
    Malek NP; Greten T; Kubicka S
    Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 17. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
    Marin JJ; Macias RI
    Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomarkers for Hepatobiliary Cancers.
    Nault JC; Villanueva A
    Hepatology; 2021 Jan; 73 Suppl 1():115-127. PubMed ID: 32045030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.